中国男男性行为HIV阳性者快速启动比克替拉韦/恩曲他滨/丙酚替诺福韦复方制剂与依非韦伦/拉米夫定/富马酸替诺福韦二吡呋酯比较:多中心随机临床试验第48周结果
这项多中心、开放标签、随机临床试验在中国HIV阳性男男性行为者中比较快速启动BIC/FTC/TAF与EFV(400 mg)+3TC+TDF的疗效与安全性。第48周BIC组病毒抑制率95.9%高于EFV组79.2%,因不良事件、死亡或失访停药比例BIC组0.7%低于EFV组16.1%,CD4计数增幅BIC组223 cells/μL高于EFV组181 cells/μL,总体不良事件发生率BIC组37.7%低于EFV组65.8%。
要点
- 第48周病毒抑制率BIC组95.9%高于EFV组79.2%。
- 因不良事件、死亡或失访停药比例BIC组0.7%低于EFV组16.1%(P < .001)。
- 总体不良事件发生率BIC组37.7%低于EFV组65.8%(P < .001)。
核心结论
- 在中国HIV阳性男男性行为者快速启动ART中,BIC/FTC/TAF比EFV(400 mg)+3TC+TDF更有效且更安全。
研究设计与样本
- 多中心、开放标签、随机临床试验,纳入年龄≥18岁、确诊HIV后14天内启动ART的男男性行为者,按1:1随机分配至EFV(400 mg)+3TC+TDF组或BIC/FTC/TAF组。
- 2021年3月至2022年7月共纳入300例,EFV组154例,BIC组146例。
- 主要终点为第48周病毒抑制(<50 copies/mL),采用美国食品药品监督管理局Snapshot分析。
主要发现
- 第48周EFV组118例(79.2%)与BIC组140例(95.9%)保持 care 且病毒抑制。
- 因不良事件、死亡或失访停药:EFV组24例(16.1%) vs BIC组1例(0.7%)(P < .001)。
- 第48周CD4计数中位增幅:EFV组181 cells/μL vs BIC组223 cells/μL(P = .020)。
- 总体不良事件发生率:EFV组65.8% vs BIC组37.7%(P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most international treatment guidelines recommend rapid initiation of antiretroviral therapy (ART) for people newly diagnosed with human immunodeficiency virus (HIV)-1 infection, but experiences with rapid ART initiation remain limited in China. We aimed to evaluate the efficacy and safety of efavirenz (400 mg) plus lamivudine and tenofovir disoproxil fumarate (EFV + 3TC + TDF) versus coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) in rapid ART initiation among men who have sex with men (MSM) who have been diagnosed with HIV. METHODS: This multicenter, open-label, randomized clinical trial enrolled MSM aged ≥18 years to start ART within 14 days of confirmed HIV diagnosis. The participants were randomly assigned in a 1:1 ratio to receive EFV (400 mg) + 3TC + TDF or BIC/FTC/TAF. The primary end point was viral suppression (<50 copies/mL) at 48 weeks per US Food and Drug Administration Snapshot analysis. RESULTS: Between March 2021 and July 2022, 300 participants were enrolled; 154 were assigned to receive EFV + 3TC + TDF (EFV group) and 146 BIC/FTC/TAF (BIC group). At week 48, 118 (79.2%) and 140 (95.9%) participants in the EFV and BIC group, respectively, were retained in care with viral suppression, and 24 (16.1%) and 1 (0.7%) participant in the EFV and BIC group (P < .001), respectively, discontinued treatment because of adverse effects, death, or lost to follow-up. The median increase of CD4 count was 181 and 223 cells/μL (P = .020), respectively, for the EFV and BIC group, at week 48. The overall incidence of adverse effects was significantly higher for the EFV group (65.8% vs 37.7%, P < .001). CONCLUSIONS: BIC/FTC/TAF was more efficacious and safer than EFV (400 mg) + 3TC + TDF for rapid ART initiation among HIV-positive MSM in China.
引用
- Wang R, Sun L, Wang X, et al. Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial. Clin Infect Dis. 2024. PMID: 38236137. doi:10.1093/cid/ciae012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。